271 related articles for article (PubMed ID: 18180113)
1. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
[TBL] [Abstract][Full Text] [Related]
2. p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas.
Santos M; Landolfi S; Olivella A; Lloveras B; Klaustermeier J; Suárez H; Alòs L; Puig-Tintoré LM; Campo E; Ordi J
Am J Surg Pathol; 2006 Nov; 30(11):1347-56. PubMed ID: 17063073
[TBL] [Abstract][Full Text] [Related]
3. p16 expression in the female genital tract and its value in diagnosis.
O'Neill CJ; McCluggage WG
Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
6. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
7. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary.
Terauchi F; Okamoto A; Nagashima T; Kobayashi Y; Moritake T; Yamamoto Y; Takakura S; Iwaki S; Ogura H
Oncol Rep; 2005 Aug; 14(2):363-8. PubMed ID: 16012716
[TBL] [Abstract][Full Text] [Related]
9. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
10. [Expression of p21(WAF1) and its relationship with p53 and PCNA protein in epithelial ovarian cancer].
Yan XJ; Liang LZ; Li DC; Li JL; Zhang CQ; Yuan SH
Ai Zheng; 2004 Jan; 23(1):74-80. PubMed ID: 14720380
[TBL] [Abstract][Full Text] [Related]
11. Expression of p16(INK4A), p53, and Rb proteins are independent from the presence of human papillomavirus genes in oral squamous cell carcinoma.
Nemes JA; Deli L; Nemes Z; Márton IJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep; 102(3):344-52. PubMed ID: 16920543
[TBL] [Abstract][Full Text] [Related]
12. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
[TBL] [Abstract][Full Text] [Related]
13. p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium.
Horn LC; Richter CE; Einenkel J; Tannapfel A; Liebert UG; Leo C
Ann Diagn Pathol; 2006 Aug; 10(4):193-6. PubMed ID: 16844559
[TBL] [Abstract][Full Text] [Related]
14. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
[TBL] [Abstract][Full Text] [Related]
16. p16, p14, p53, and cyclin D1 expression and HPV analysis in small cell carcinomas of the uterine cervix.
Horn LC; Lindner K; Szepankiewicz G; Edelmann J; Hentschel B; Tannapfel A; Bilek K; Liebert UG; Richter CE; Einenkel J; Leo C
Int J Gynecol Pathol; 2006 Apr; 25(2):182-6. PubMed ID: 16633070
[TBL] [Abstract][Full Text] [Related]
17. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
18. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
[TBL] [Abstract][Full Text] [Related]
19. Comparative proteomics of ovarian epithelial tumors.
An HJ; Kim DS; Park YK; Kim SK; Choi YP; Kang S; Ding B; Cho NH
J Proteome Res; 2006 May; 5(5):1082-90. PubMed ID: 16674097
[TBL] [Abstract][Full Text] [Related]
20. P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma.
Mellin Dahlstrand H; Lindquist D; Björnestål L; Ohlsson A; Dalianis T; Munck-Wikland E; Elmberger G
Anticancer Res; 2005; 25(6C):4375-83. PubMed ID: 16334111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]